ERBB2 and breast carcinoma: The potential of exosomes as cancer biomarkers has gained attention in recent years, with our study contributing to this growing field by demonstrating the ability to detect HER2-positive exosomes in plasma samples from breast cancer patients using SP-IRIS technology.